Cell-based therapies are emerging as a transformative approach in healthcare, with the global cell therapy market expected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Several biotech companies announced significant milestones: Avaí Bio and Austrianova completed a Master Cell Bank for α-Klotho anti-aging therapy; Geron presented real-world evidence for RYTELO in myelodysplastic syndromes; BioAge Labs reported Phase 1 results for BGE-102 showing strong inflammatory biomarker reductions; Lineage Cell Therapeutics presented 3-year data for OpRegen cell therapy in geographic atrophy; and Fate Therapeutics advanced FT819 CAR T-cell therapy with FDA recognition.

Geron Corporation announced it will release its first quarter 2026 financial results on May 6, 2026, followed by a conference call and webcast at 8:00 a.m. Eastern Time. The commercial-stage biopharmaceutical company continues to advance its telomerase inhibitor RYTELO® (imetelstat), which is approved in the U.S. and EU for treating lower-risk myelodysplastic syndromes, and is conducting a Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis.

Geron Corporation announced the appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary. Williams brings extensive biopharmaceutical industry experience from previous roles at Vanda Pharmaceuticals, AgNovos Bioscience, and Stryker Corporation. The appointment is part of recent leadership strengthening efforts at the commercial-stage blood cancer treatment company.

Geron Corporation announced that its management team will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The commercial-stage biopharmaceutical company, which markets RYTELO® (imetelstat) for treating lower-risk myelodysplastic syndromes, continues to conduct pivotal Phase 3 trials in JAK-inhibitor relapsed/refractory myelofibrosis and other hematologic malignancies.

Geron Corporation reported full year 2025 RYTELO net product revenue of $184 million with Q4 revenue of $48 million. The company ended 2025 with $401 million in cash and expects 2026 RYTELO revenue between $220-240 million. Operating expenses totaled $255 million in 2025, within guidance. Geron implemented a workforce reduction of approximately one-third in December 2025 and reiterated focus on driving U.S. commercial growth while pursuing international expansion opportunities.

Geron Corporation plans to reduce workforce by one-third and streamline operations to improve financial discipline, focusing on RYTELO commercial growth and clinical development while reducing 2026 operating expenses.

Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.

Law firm investigating potential claims against Geron Corporation regarding alleged misleading statements about drug Rytelo's launch and growth potential during February 2024-2025 period.

Biotechnology company Cassava Sciences announced the appointment of Dawn C. Bir to its Board of Directors, bringing extensive biopharmaceutical executive experience to support the company's clinical development of simufilam for TSC-related epilepsy.

Geron Corporation has appointed four new executives, including Ahmed ElNawawi as Chief Commercial Officer, to lead commercial strategy and drive growth for its blood cancer treatment RYTELO®.

SpyGlass Pharma announced the appointment of Elizabeth O'Farrell to its Board of Directors, bringing over 30 years of healthcare industry experience. She will serve as an Independent Director and Chair of the Audit Committee, supporting the company's advancement of its Drug Delivery Platform for glaucoma management.

Law firm investigating potential claims against Geron Corporation regarding alleged misrepresentations about drug Rytelo's launch and growth potential during February 2024-2025 period.